2021

主页/标签: 2021

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals [...]

2021-12-29T06:00:00+00:00分类:新闻通稿|标签:|

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Oravax's oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax's oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. [...]

2021-12-14T08:00:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals Appoints Chief Legal Officer

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, [...]

2021-12-08T07:30:00+00:00分类:新闻通稿|标签:|

Oramed to Join MSCI USA Small Cap Index

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its common stock will be added to the MSCI USA Small Cap Index effective [...]

2021-11-24T08:40:00+00:00分类:新闻通稿|标签:|

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 75% of the 675 patients planned for its [...]

2021-11-23T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

- Millions of people in the region could benefit from the COVID-19 vaccine candidate- faster, easier, without the cold chain: The Oravax Oral Vaccine - The new partnership builds on the respective strengths of Oravax Medical and Genomma Lab to create compelling value for both [...]

2021-11-18T07:40:00+00:00分类:新闻通稿|标签:|

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

NEW YORK, November 11, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright [...]

2021-11-11T09:25:00+00:00分类:新闻通稿|标签:|

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has closed its previously announced registered direct offering of 2,000,000 shares [...]

2021-11-08T08:10:00+00:00分类:新闻通稿|标签:|

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has entered into definitive agreements with several institutional and accredited  [...]

2021-11-03T11:59:00+00:00分类:新闻通稿|标签:|

Oramed Announces Oravax’s Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial

NEW YORK, Oct. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its majority-owned subsidiary, Oravax Medical Inc. (www.ora-vax.com), has received clearance from the South African Health [...]

2021-10-29T07:25:00+00:00分类:新闻通稿|标签:|